Truist Financial recently began coverage on shares of Voyager Therapeutics, a clinical-stage gene therapy company engaged in developing treatments for severe neurological diseases. The report issued by Truist Financial assigned a “buy” rating and set a $18.00 price target on the stock, implying potential upside of 67.29% from its current price. Such bold projections reflect the promising nature of Voyager’s pipeline of gene therapy programs that includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01.
However, amidst the excitement surrounding Voyager Therapeutics’ stock is news of insider trading activity within the company. COO Robin Swartz sold 3,654 shares at an average price of $7.76 for a total value of $28,355.04; subsequently disclosing the sale in a filing with the Securities & Exchange Commission (SEC). CEO Alfred Sandrock also sold 7,437 shares at an average price of $7.83 for a total transaction of $58,231.71 on Monday – making insiders collectively sell 26,653 shares worth $205,855 over ninety days.
While analysts may view this activity as indicative of bearish sentiments towards the company’s future prospects – some might say this analysis is too hasty. One can interpret such insider selling as profit-taking connected to unique circumstances or liquidity events such as vesting options from fellow executives during grant processing periods.
As investors make decisions based on various factors such as observations over past earnings reports coupled with sales numbers or investing strategies arising from interpreting SEC filings we cannot discount market volatility given COVID-19’s impact on global economies including investor sentiment toward biotech companies undergoing clinical trials.
Ultimately investors will need to decide if they have faith in Voyager Therapeutics’ ability to execute or not after evaluating what their due diligence tells them concerning both portfolio diversification factors and any early research showing clinical trial outcomes. With that said, this coverage initiation from Truist Financial ought to pique the interest of healthcare investors.
Voyager Therapeutics captures the attention of investors with potential for growth
The biotech company, Voyager Therapeutics, has recently gained the attention of hedge funds as it continues its upward trend in the stock market. Shares of Voyager Therapeutics opened at $10.76 on Wednesday, and have a fifty-day moving average of $7.78 and a two-hundred day moving average of $7.11. This exciting company has captured the attention of investors with a market cap of $468.17 million and a beta of 1.12.
Several brokerages recently released reports on the company, including StockNews.com who downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on March 24th. Meanwhile, Oppenheimer initiated coverage on shares of Voyager Therapeutics in early March and issued an “outperform” rating along with a $14 price target for the company.
Institutional investors and hedge funds have also taken notice of Voyager’s potential for growth. For example, PDT Partners LLC purchased a new stake worth approximately $60,000 during Q2 this year while Boothbay Fund Management LLC acquired new shares in Q4 last year valued at $93,000. Furthermore, Royal Bank of Canada increased its holdings by an astonishing 1,746.8% during Q3 last year by purchasing 11,354 additional shares valued at $71,000.
Voyager Therapeutics is currently trading at -8.82 P/E ratio which is commonly seen when dealing with emerging market companies like this one that dedicate heavy reinvestment to R&D spending to increase output or production later down the line.
All signs indicate that Voyager Therapeutics is heading toward significant growth in the future thanks to these recent investments by some major players in finance that show their confidence in this forward-leaning company with great promise for years to come!
Source: beststocks.com
Truist Financial recently began coverage on shares of Voyager Therapeutics, a clinical-stage gene therapy company engaged in developing treatments for severe neurological diseases. The report issued by Truist Financial assigned a “buy” rating and set a $18.00 price target on the stock, implying potential upside of 67.29% from its current price. Such bold projections reflect the promising nature of Voyager’s pipeline of gene therapy programs that includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01.
However, amidst the excitement surrounding Voyager Therapeutics’ stock is news of insider trading activity within the company. COO Robin Swartz sold 3,654 shares at an average price of $7.76 for a total value of $28,355.04; subsequently disclosing the sale in a filing with the Securities & Exchange Commission (SEC). CEO Alfred Sandrock also sold 7,437 shares at an average price of $7.83 for a total transaction of $58,231.71 on Monday – making insiders collectively sell 26,653 shares worth $205,855 over ninety days.
While analysts may view this activity as indicative of bearish sentiments towards the company’s future prospects – some might say this analysis is too hasty. One can interpret such insider selling as profit-taking connected to unique circumstances or liquidity events such as vesting options from fellow executives during grant processing periods.
As investors make decisions based on various factors such as observations over past earnings reports coupled with sales numbers or investing strategies arising from interpreting SEC filings we cannot discount market volatility given COVID-19’s impact on global economies including investor sentiment toward biotech companies undergoing clinical trials.
Ultimately investors will need to decide if they have faith in Voyager Therapeutics’ ability to execute or not after evaluating what their due diligence tells them concerning both portfolio diversification factors and any early research showing clinical trial outcomes. With that said, this coverage initiation from Truist Financial ought to pique the interest of healthcare investors.
Voyager Therapeutics captures the attention of investors with potential for growth
The biotech company, Voyager Therapeutics, has recently gained the attention of hedge funds as it continues its upward trend in the stock market. Shares of Voyager Therapeutics opened at $10.76 on Wednesday, and have a fifty-day moving average of $7.78 and a two-hundred day moving average of $7.11. This exciting company has captured the attention of investors with a market cap of $468.17 million and a beta of 1.12.
Several brokerages recently released reports on the company, including StockNews.com who downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on March 24th. Meanwhile, Oppenheimer initiated coverage on shares of Voyager Therapeutics in early March and issued an “outperform” rating along with a $14 price target for the company.
Institutional investors and hedge funds have also taken notice of Voyager’s potential for growth. For example, PDT Partners LLC purchased a new stake worth approximately $60,000 during Q2 this year while Boothbay Fund Management LLC acquired new shares in Q4 last year valued at $93,000. Furthermore, Royal Bank of Canada increased its holdings by an astonishing 1,746.8% during Q3 last year by purchasing 11,354 additional shares valued at $71,000.
Voyager Therapeutics is currently trading at -8.82 P/E ratio which is commonly seen when dealing with emerging market companies like this one that dedicate heavy reinvestment to R&D spending to increase output or production later down the line.
All signs indicate that Voyager Therapeutics is heading toward significant growth in the future thanks to these recent investments by some major players in finance that show their confidence in this forward-leaning company with great promise for years to come!
Source: beststocks.com
